Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised …
EJ Gane, SK Roberts, CAM Stedman, PW Angus… - The Lancet, 2010 - thelancet.com
Background Present interferon-based standard of care treatment for chronic hepatitis C virus
(HCV) infection is limited by both efficacy and tolerability. We assessed the safety …
(HCV) infection is limited by both efficacy and tolerability. We assessed the safety …
Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised …
EJ Gane, SK Roberts, CAM Stedman, PW Angus… - Lancet, 2010 - thelancet.com
Background Present interferon-based standard of care treatment for chronic hepatitis C virus
(HCV) infection is limited by both efficacy and tolerability. We assessed the safety …
(HCV) infection is limited by both efficacy and tolerability. We assessed the safety …
Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised …
EJ Gane, SK Roberts, CAM Stedman, PW Angus… - 2010 - cabidigitallibrary.org
Background-Present interferon-based standard of care treatment for chronic hepatitis C virus
(HCV) infection is limited by both efficacy and tolerability. We assessed the safety …
(HCV) infection is limited by both efficacy and tolerability. We assessed the safety …
Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised …
EJ Gane, SK Roberts, CAM Stedman, PW Angus… - The Lancet, 2010 - infona.pl
Present interferon-based standard of care treatment for chronic hepatitis C virus (HCV)
infection is limited by both efficacy and tolerability. We assessed the safety, tolerability, and …
infection is limited by both efficacy and tolerability. We assessed the safety, tolerability, and …
[引用][C] Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a …
EJ GANE, SK ROBERTS, T CHU… - Lancet (British …, 2010 - pascal-francis.inist.fr
Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir
for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind …
for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind …
Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised …
EJ Gane, SK Roberts, CA Stedman… - Lancet (London …, 2010 - europepmc.org
Background Present interferon-based standard of care treatment for chronic hepatitis C virus
(HCV) infection is limited by both efficacy and tolerability. We assessed the safety …
(HCV) infection is limited by both efficacy and tolerability. We assessed the safety …
Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised …
EJ Gane, SK Roberts, CAM Stedman, PW Angus… - 2010 - pubmed.ncbi.nlm.nih.gov
Background Present interferon-based standard of care treatment for chronic hepatitis C virus
(HCV) infection is limited by both efficacy and tolerability. We assessed the safety …
(HCV) infection is limited by both efficacy and tolerability. We assessed the safety …
[引用][C] Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a …
EJ Gane, SK Roberts, CAM Stedman, PW Angus… - The Lancet, 2010 - cir.nii.ac.jp
Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for
chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind …
chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind …
Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised …
EJ Gane, SK Roberts, CAM Stedman, PW Angus… - The Lancet, 2010 - Elsevier
BACKGROUND: Present interferon-based standard of care treatment for chronic hepatitis C
virus (HCV) infection is limited by both efficacy and tolerability. We assessed the safety …
virus (HCV) infection is limited by both efficacy and tolerability. We assessed the safety …
[引用][C] Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a …
G EJ - Lancet, 2010 - cir.nii.ac.jp
Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for
chronic hepatitis C genotype 1 infection (INFORM-1) : a randomised. double-blind …
chronic hepatitis C genotype 1 infection (INFORM-1) : a randomised. double-blind …